Presentation TCT 2016 Low-Flow Aortic Stenosis: Clinical Outcomes After TAVR Presenter: A. Pieter Kappetein, Allan Schwartz, Howard C. Herrmann October 30, 2016
Presentation TCT 2016 TCT 1559: TMVR Using a Fully Repositionable (LOTUS) Valve in a Patient With Severe MAC, Septal Hypertrophy, Left Main Disease, and Severe Aortic Stenosis: Importance of Preprocedural Planning Presenter: Henrique B. Ribeiro, Dimytri Alexandre Siqueira, Chris Meduri October 30, 2016
Presentation TCT 2016 Low-Flow Aortic Stenosis: Pathophysiology, Syndrome Classification, and Prognosis Presenter: A. Pieter Kappetein, Allan Schwartz, Philippe Pibarot October 30, 2016
Presentation TCT 2016 Transcatheter Valve-in-Valve Therapy: Clinical and Technical Pearls Presenter: A. Pieter Kappetein, Allan Schwartz, Vinayak Bapat October 30, 2016
Presentation TCT 2016 Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies Presenter: A. Pieter Kappetein, Allan Schwartz, Danny Dvir October 30, 2016
Presentation TCT 2016 TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples) Presenter: A. Pieter Kappetein, Allan Schwartz, Mathew Williams October 30, 2016
Presentation TCT 2016 TCT 515: Prognostic Implications of Instantaneous Wave-Free Ratio (iFR) and Resting Distal-to-Aortic Pressure Ratio (Pd/Pa) Compared with Fractional Flow Reserve (FFR). A 10-Year Follow-Up Study After Deferral of Revascularization Presenter: Michalis Hamilos, Pim A.L. Tonino October 30, 2016
Presentation TCT 2016 Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR Presenter: A. Pieter Kappetein, Allan Schwartz, Lars Sondergaard October 30, 2016
Presentation TCT 2016 Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR! Presenter: Russell A. Brandwein, Isaac George October 30, 2016
Presentation TCT 2016 Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection! Presenter: Patrick T. O'Gara, Alec S. Vahanian, David J. Cohen October 30, 2016
Presentation TCT 2016 Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It! Presenter: Russell A. Brandwein, Susheel K. Kodali October 30, 2016
Presentation TCT 2016 Treatment Options After Unsuccessful Aortic Valve Replacement Presenter: Alejandro Cherro, Oscar A. Mendiz October 30, 2016
Presentation TCT 2016 Simultaneous TAVR and Endovascular Aortic Aneurysm Repair Presenter: Habib Gamra, Mahmoud Hashemian, Abdullah Shehab, Walid Ouertani October 30, 2016
Presentation TCT 2016 Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes! Presenter: Patrick T. O'Gara, Alec S. Vahanian, Lars G. Svensson October 30, 2016
Presentation TCT 2016 Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling! Presenter: Patrick T. O'Gara, Alec S. Vahanian, Stephan Windecker October 30, 2016
Presentation TCT 2016 TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement Presenter: Jean-Claude Laborde, Azfar G. Zaman October 30, 2016
Presentation TCT 2016 Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma October 30, 2016
Presentation TCT 2016 Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack October 30, 2016
Presentation TCT 2016 Management Options for Postsurgical Paravalvular Aortic Regurgitation Presenter: Alejandro Cherro, Fernando Cura October 30, 2016
Presentation TCT 2016 Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat October 30, 2016